Social Capital Suvretta Holdings Corp I

Akili, Inc. is a digital medicine company, which engages in the development of cognitive treatments through technologies. Its leveraging technologies designed to directly target the brain establishes a new category of medicine that is validated through clinical trials like a drug or medical device, but experienced like entertainment. The company is headquartered in Boston, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Akili, Inc. is a digital medicine company, which engages in the development of cognitive treatments through technologies. Its technologies are designed to directly target the physiology of the brain. The company was founded by W. Edward Martucci II and Adam Gazzaley in December 2020 and is headquartered in Boston, MA.

Shares in Social Capital Suvretta Holdings (NASDAQ: DNAA ) rose sharply on news it completed its merger with Akili Interactive, which hopes to treat brain conditions using video games. After the market opens on August 22, the company will trade as AKLI.

DNAA Stock Races 200% Higher as Akili SPAC Merger Closes

Akili announced it has completed its previously announced business combination with Social Capital Suvretta Holdings Corp. I (DNAA). These are the details.

Akili Completes Business Combination With Social Capital Suvretta Holdings Corp. I (DNAA)

BOSTON & PALO ALTO, Calif.--(BUSINESS WIRE)---- $DNAA #DTx--Digital Medicine Leader Akili to List on Nasdaq Following Successful Business Combination with Social Capital Suvretta Holdings Corp. I

Digital Medicine Leader Akili to List on Nasdaq Following Successful Business Combination with Social Capital Suvretta Holdings Corp. I

WINSTON-SALEM, N,C. and PALO ALTO, Calif., July 12, 2022 (GLOBE NEWSWIRE) --  ProKidney LP (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on CKD, and Social Capital Suvretta Holdings Corp. III (“SCS”) (Nasdaq: DNAC), a special purpose acquisition company, today completed their previously announced business combination. The newly formed company is named ProKidney Corp. and its Class A ordinary shares will commence trading on the Nasdaq Capital Market (“Nasdaq”) under the symbol “PROK” on July 12, 2022.

Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to List on the Nasdaq Following Business Combination with Social Capital Suvretta Holdings Corp. III

PureTech Health PLC

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Akili Announces Public Company Board of Director Nominees

PureTech Founded Entity Akili Announces Public Company Board of Director Nominees

BOSTON--(BUSINESS WIRE)--Akili Interactive (“Akili”), a leading digital medicine company pioneering the development of cognitive treatments through game-changing technologies, today announced the nominees for its future board of directors, effective upon the closing of Akili's business combination with Social Capital Suvretta Holdings Corp. I (“SCS”) (Nasdaq: DNAA), subject to customary closing conditions. Shares of the new public company's common stock are expected to trade on Nasdaq under the

Akili Announces Public Company Board of Director Nominees

BOSTON--(BUSINESS WIRE)--Akili Interactive (“Akili”), a leading cognitive medicine company improving health through game-changing technologies, today announced that the American Journal of Psychiatry has published findings from the STARS-MDD clinical trial evaluating Akili's AKL-T03 digital therapeutic as a potential treatment for attention impairments in adults with major depressive disorder (MDD) when used alongside antidepressant medication. More than 16 million people in the United States a

The American Journal of Psychiatry Publishes Data Demonstrating Akili Interactive's Digital Therapeutic AKL-T03 Improves Cognitive Impairments in Adults with Major Depressive Disorder When Combined with Antidepressant Medication

BOSTON--(BUSINESS WIRE)--Akili Interactive (“Akili” or the “Company”), a leading digital medicine company pioneering the development of cognitive treatments through game-changing technologies, today announced that management will present at Chardan's Prescription Digital Therapeutics Half-Day Summit on Monday, April 11, 2022 at 2:00 p.m. E.T. More information on the event can be found here. About Akili Akili is pioneering the development of cognitive treatments through game-changing technologie

Akili to Present at Chardan's Prescription Digital Therapeutics Half-Day Summit

BOSTON--(BUSINESS WIRE)--Akili Appoints Game Industry Veteran Jon David as Chief Product Officer

Game Industry Veteran Behind Bejeweled, Plants vs. Zombies Joins Akili as Chief Product Officer

BOSTON--(BUSINESS WIRE)---- $DNAA #DTx--Akili has been named to Fast Company's Annual list of the World's 50 Most Innovative Companies

Akili Named to Fast Company's Annual List of the World's 50 Most Innovative Companies for 2022

BOSTON--(BUSINESS WIRE)-- #DTx--Akili Management to Present at Cowen's 42nd Annual Health Care Conference

Akili to Present at Cowen's 42nd Annual Health Care Conference

BOSTON--(BUSINESS WIRE)---- $DNAA #DTx--Akili Chief Financial Officer and Vice President of Marketing will speak at leading digital therapeutics conference, DTx West

Akili to Speak on Integrating Digital Therapeutics Into Mainstream Healthcare at DTx West 2022

BOSTON--(BUSINESS WIRE)---- $DNAA #DTx--New data published from a study of Akili's EndeavorRx shows the how the digital therapeutic effects brain activity of a child with ADHD

PLOS ONE Publishes Clinical Study Results and EEG Data Showing Akili Digital Therapeutic EndeavorRx® Activates Systems in Brain Key to Attentional Functioning

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Akili Announces Filing of Registration Statement on S-4 in Connection with its Proposed Business Combination with SCS

PureTech Founded Entity Akili Interactive Announces Filing of Registration Statement on S-4 in Connection with its Proposed Business Combination with Social Capital Suvretta Holdings Corp. I

BOSTON & PALO ALTO, Calif.--(BUSINESS WIRE)---- $DNAA #DTx--Akili Announces Filing of S-4 in Connection with its Proposed Business Combination with Social Capital Suvretta Holdings Corp. I

Akili Interactive Announces Filing of Registration Statement on S-4 in Connection with its Proposed Business Combination with Social Capital Suvretta Holdings Corp. I

DNAA stock is on the rise today after news its blank-check company, backed by Chamath Palihapitiya, is merging with Akili Interactive. The post DNAA Stock Alert: Chamath Palihapitiya's SPAC Preps for Akili Interactive Merger appeared first on InvestorPlace.

DNAA Stock Alert: Chamath Palihapitiya's SPAC Preps for Akili Interactive Merger

A biotech focused SPAC launched by frequent SPAC sponsor Chamath Palihapitiya announced a merger deal Wednesday morning. The SPAC Deal: Palihapitiya's Social Capital Suvretta Holdings Corp I (NASDAQ: DNAA) announced a SPAC merger with Akili Interactive, valuing the company at an equity value of $1 billion.

Chamath Palihapitiya Announces SPAC Deal For Akili: Revolutionary Digital Therapy For Mental Illness

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with SCS

PureTech Founded Entity Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I

BOSTON & PALO ALTO, Calif.--(BUSINESS WIRE)---- $DNAA #DTx--Digital medicine leader Akili to become publicly-traded company through agreement with Social Capital Suvretta Holdings Corp. I (Nasdaq: DNAA)

Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I

Social Capital Suvretta Holdings Corp III

The 2022 year has started quietly for SPACs, with no deals announced in the first five trading days of the year. Although two new SPAC rumors have popped up since the market closed on Friday and both involve a well-known name in the SPAC space.

News for Social Capital Suvretta Holdings Corp I Stock (DNAA)